Parkinson's drug may impact gum disease risk
NCT ID NCT07405268
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether the Parkinson's drug Levodopa-Benserazide affects gum health and inflammation. Researchers will measure gum health and saliva markers in 136 people, including Parkinson's patients with and without gum disease, and healthy controls. The goal is to understand how this common medication might influence oral health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Levodopa-Benserazide
- What this could lead to
- If successful, this could help doctors understand how Parkinson's medication affects gum health, potentially leading to better dental care for patients.
- What could go wrong
- This is a small, observational study that only measures markers, not a treatment trial. Results may not apply to all Parkinson's patients or lead to direct changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği Fakültesi
Ankara, 06010, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nature's mouthwash: could tea tree oil and thyme tame gum disease?
- Blood-Derived clot may regrow bone in gum disease
- Parkinson's pain: could a new Add-On drug bring relief?
- Can virtual games retrain the brain to restore balance?
- Can gum disease be stopped by targeting these genes?
- Could saliva hold the key to understanding gum disease?